Top

Advances in Therapy

Published in:

Open Access 01-01-2015 | Review

Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review

Authors: Luciano Mariani, Patrizia Vici, Barbara Suligoi, Giovanni Checcucci-Lisi, Rosybel Drury

Published in: Advances in Therapy | Issue 1/2015

Abstract

Introduction

Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination.

Methods

We performed a systematic literature search in PubMed to identify all published studies on 4HPV vaccination, including those that assessed the impact of 4HPV vaccination programs on the incidence of GWs at a population level around the world.

Results

A total of 354 records were identified in the PubMed search. After screening and obtaining full papers for 56 publications, 16 publications presenting data on the impact or effectiveness of 4HPV vaccination on GWs were identified. These reported data on the impact or effectiveness of 4HPV in six countries [Australia (n = 6), New Zealand (n = 2), United States (n = 3), Denmark (n = 2), Germany (n = 1), and Sweden (n = 2)]. In Australia, no GWs were diagnosed in women aged <21 years who reported being vaccinated. A 92.6% reduction in GWs incidence was reported for all women in this age group, where the vaccine uptake rate (VUR) was 70% for 3 doses. The highest reductions were reported in countries with high VURs, mostly through school-based vaccination programs, although high VURs were obtained with some non-school-based programs.

Conclusion

The results are coherent with the GWs incidence reduction reported in clinical trials and are an early indicator of what can be expected for the long-term clinical impact on vaccine-type HPV-related cancers.

Available only for authorised users

Aubin F, Pretet JL, Jacquard AC, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a large French national study (EDiTH IV). Clin Infect Dis. 2008;47(5):610–5.PubMedCrossRef

Centres for Disease Control and Prevention. Genital HPV infection—fact sheet: http://www.cdc.gov/std/hpv/stdfact-hpv.htm. Accessed Feb 3, 2013.

Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–14.PubMedCrossRef

Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39.PubMedCentralPubMedCrossRef

Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35(Suppl 2):S210–24.PubMedCrossRef

Dominiak-Felden G, Cohet C, Atrux-Tallau S, Gilet H, Tristram A, Fiander A. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC Public Health. 2013;13(1):1065.PubMedCentralPubMedCrossRef

Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K. Genital warts and cost of care in England. Sex Transm Infect. 2011;87(6):464–8.PubMedCentralPubMedCrossRef

Lanitis T, Carroll S, O’Mahony C, et al. The cost of managing genital warts in the UK. Int J STD AIDS. 2012;23(3):189–94.PubMedCrossRef

Baldo V, Cocchio S, Buja A, et al. Hospitalization for diseases attributable to human papillomavirus in the Veneto Region (North-East Italy). BMC Infect Dis. 2013;13:462.PubMedCentralPubMedCrossRef

10.

Baio G, Capone A, Marcellusi A, Mennini FS, Favato G. Economic burden of human papillomavirus-related diseases in Italy. PLoS One. 2012;7(11):e49699.PubMedCentralPubMedCrossRef

11.

European Medicines Agency. European public assessment report (EPAR) for Gardasil: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp&mid=WC0b01ac058001d125&murl=menus/medicines/medicines.jsp&jsenabled=true. Accessed Oct 16, 2014.

12.

Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction—the first five years. Vaccine. 2012;30(Suppl 5):F139–48.PubMedCrossRef

13.

Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325–39.PubMedCrossRef

14.

Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG. 2008;115(8):947–56.PubMedCrossRef

15.

Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28–41.PubMedCentralPubMedCrossRef

16.

Suligoi B, Salfa MC, Mariani L, et al. A new surveillance gynecological network to assess the incidence and prevalence of genital warts in the Italian female population: lessons learned. Minerva Ginecol. 2013;65(5):577–85.PubMed

17.

Vittori G, Matteelli A, Boselli F, Naldi L, Emberti Gialloreti L. A new approach to estimate genital warts incidence and prevalence in the Italian general female population. Ital J Gynaecol Obstet. 2008;20(1):33–4.

18.

Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.PubMedCrossRef

19.

Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39–44.PubMedCrossRef

20.

Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85(7):499–502.PubMedCrossRef

21.

Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544–7.PubMedCrossRef

22.

Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015;211(1):91–9.PubMedCrossRef

23.

Liu B, Donovan B, Brotherton JM, Saville M, Kaldor JM. Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011. Sex Transm Infect. 2014;90(7):532–7.PubMedCrossRef

24.

Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J. 2011;124(1339):51–8.PubMed

25.

Wilson N, Morgan J, Baker MG. Evidence for effectiveness of a national HPV vaccination programme: national prescription data from New Zealand. Sex Transm Infect. 2014;90(2):103.PubMedCrossRef

26.

Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine-effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health. 2012;102(5):833–5.PubMedCentralPubMedCrossRef

27.

Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103(8):1428–35.PubMedCentralPubMedCrossRef

28.

Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR. 2013;20(2):17–20.PubMed

29.

Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130–5.PubMed

30.

Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis. 2013;57(7):929–34.PubMedCrossRef

31.

Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany—an ecologic study. Sex Transm Dis. 2013;40(1):28–31.PubMedCrossRef

32.

Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206(6):860–6.PubMedCrossRef

33.

Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469–74.PubMedCentralPubMedCrossRef

34.

Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med. 2011;53(Suppl 1):S29–35.PubMedCrossRef

35.

Centres for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccination in males—Advisory Committee on Immunization Practices (ACIP) 2011. MMWR. 2011;60(50):1705–8.

36.

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson HW, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(RR-2):1–24.PubMed

37.

Dorell C, Stokley S, Yankey D, Liang JL, Markowitz LE. National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. MMWR. 2011;60(33):1117–23.

38.

Williams WW, Lu P-J, Singleton JA, Worley PM, Byrd KK, Markowitz LE. Adult vaccination coverage—United States, 2010. MMWR. 2012;61(4):66–72.

39.

Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One. 2014;9(9):e105967.PubMedCentralPubMedCrossRef

40.

Australian Government Department of Health. Gardasil (quadrivalent human papillomavirus vaccine): http://www.tga.gov.au/safety/alerts-medicine-gardasil-130516.htm#.Uu-Qjfl5OSo. Accessed Feb 3, 2013.

41.

Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine. 2012;30(Suppl 5):F1–11.PubMedCrossRef

42.

Brill D. Australia launches national scheme to vaccinate boys against HPV. BMJ. 2013;346:f924.PubMedCrossRef

43.

Austrian Federal Ministry of Health. http://www.bmg.gv.at/home/Startseite/aktuelle_Meldungen/HPV_Impfung_gratis. Accessed Dec 3, 2014.

44.

Austrian Vaccination Schedule 2014: http://bmg.gv.at/cms/home/attachments/8/9/4/CH1100/CMS1389365860013/impfplan2014.pdf. Accessed Dec 3, 2014.

45.

Baron J, Beresford P, Gould J, Patel K, Nash P, Freer M. Time to vaccinate boys against HPV infection and cancer, say parliamentarians with special interest in public health. BMJ. 2014;349:g5789.PubMedCrossRef

46.

Howell-Jones R, Soldan K, Wetten S, et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208(9):1397–403.PubMedCentralPubMedCrossRef

47.

Clarke E, Board C, Patel N, Atkinson L, Tulloch H, Patel R. Why are anogenital warts diagnoses decreasing in the UK: bivalent human papillomavirus (HPV) vaccine cross-protection or failure to examine? Sex Transm Infect. 2014;90(8):587.PubMedCrossRef

48.

Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32(1):26–32.PubMedCentralPubMedCrossRef

49.

Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110(11):2804–11.PubMedCrossRef

50.

Szarewski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013;208(9):1391–6.PubMedCentralPubMedCrossRef

51.

Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–93.PubMedCrossRef

52.

Delere Y, Remschmidt C, Leuschner J, et al. Human papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis. 2014;14(1):87.PubMedCentralPubMedCrossRef

53.

Merckx M, Broeck DV, Benoy I, Depuydt C, Weyers S, Arbyn M. Early effects of human papillomavirus vaccination in Belgium. Eur J Cancer Prev. 2014. doi:10.1097/cej.0000000000000067.

54.

Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;25(7):915–22.

55.

Budd AC, Brotherton JM, Gertig DM, Chau T, Drennan KT, Saville M. Cervical screening rates for women vaccinated against human papillomavirus. Med J Aust. 2014;201(5):279–82.PubMedCrossRef

56.

Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.PubMedCentralPubMedCrossRef

57.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227.PubMedCentralPubMedCrossRef

58.

Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013;53(6):679–82.PubMedCrossRef

59.

McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil(R)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs 2014;74(11):1253–83.PubMedCrossRef

60.

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS): http://wwwn.cdc.gov/nndss/. Accessed Feb 28, 2014.

Title: Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review
Authors: Luciano Mariani
Patrizia Vici
Barbara Suligoi
Giovanni Checcucci-Lisi
Rosybel Drury
Publication date: 01-01-2015
Publisher: Springer Healthcare
Published in: Advances in Therapy / Issue 1/2015
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-015-0178-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review

Abstract

Introduction

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

A Review of Uric Acid, Crystal Deposition Disease, and Gout

Use of Inhaled Tobramycin in Cystic Fibrosis

Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial

Cost-Effectiveness of Point-of-Care C-Reactive Protein Tests for Respiratory Tract Infection in Primary Care in England

Current Adjuvant Therapeutic Approaches for Pancreatic Cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page